- Home
- DTSQ vs PROK Comparison
DTSQ vs PROK Comparison
Compare DTSQ & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSQ
- PROK
- Stock Information
- Founded
- DTSQ 2022
- PROK 2015
- Country
- DTSQ United States
- PROK United States
- Employees
- DTSQ N/A
- PROK N/A
- Industry
- DTSQ
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DTSQ
- PROK Health Care
- Exchange
- DTSQ NYSE
- PROK Nasdaq
- Market Cap
- DTSQ 91.7M
- PROK 85.5M
- IPO Year
- DTSQ 2024
- PROK N/A
- Fundamental
- Price
- DTSQ $10.39
- PROK $4.74
- Analyst Decision
- DTSQ
- PROK Buy
- Analyst Count
- DTSQ 0
- PROK 4
- Target Price
- DTSQ N/A
- PROK $5.33
- AVG Volume (30 Days)
- DTSQ 531.0
- PROK 33.1M
- Earning Date
- DTSQ 01-01-0001
- PROK 08-08-2025
- Dividend Yield
- DTSQ N/A
- PROK N/A
- EPS Growth
- DTSQ N/A
- PROK N/A
- EPS
- DTSQ 0.28
- PROK N/A
- Revenue
- DTSQ N/A
- PROK $306,000.00
- Revenue This Year
- DTSQ N/A
- PROK $54.34
- Revenue Next Year
- DTSQ N/A
- PROK N/A
- P/E Ratio
- DTSQ $37.07
- PROK N/A
- Revenue Growth
- DTSQ N/A
- PROK N/A
- 52 Week Low
- DTSQ $9.96
- PROK $0.46
- 52 Week High
- DTSQ $10.49
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- DTSQ N/A
- PROK 92.14
- Support Level
- DTSQ N/A
- PROK $0.54
- Resistance Level
- DTSQ N/A
- PROK $7.13
- Average True Range (ATR)
- DTSQ 0.00
- PROK 0.62
- MACD
- DTSQ 0.00
- PROK 0.47
- Stochastic Oscillator
- DTSQ 0.00
- PROK 68.59
About DTSQ DT CLOUD STAR ACQUISITION CORP
DT Cloud Star Acquisition Corp is a blank check company.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.